Amit Gupta, Sweety Gupta, Rishit Mani, Prashant Durgapal, Bela Goyal, Deepak Rajput, Shalinee Rao, Puneet Dhar, Manoj Gupta, Sanjeev Kishore, Ravi Kant
{"title":"人表皮生长因子受体2、Survivin、zeste同源物增强子-2、环氧化酶-2、p53和p16分子标志物在胆囊癌组织中的表达","authors":"Amit Gupta, Sweety Gupta, Rishit Mani, Prashant Durgapal, Bela Goyal, Deepak Rajput, Shalinee Rao, Puneet Dhar, Manoj Gupta, Sanjeev Kishore, Ravi Kant","doi":"10.4103/jcar.JCar_4_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gallbladder cancer exhibits striking variability in the global rates, reaching epidemic levels for some regions and ethnicities. The basis of its variability resides in differences in environmental exposure and intrinsic genetic predisposition to carcinogenesis. There is little information present regarding genetic and molecular alterations in gall bladder cancer (GBC). We, therefore, have evaluated the molecular marker expression in GBC and studied their correlation with clinicopathological staging.</p><p><strong>Materials and methods: </strong>This prospective observational study was conducted on newly diagnosed GBC patients from July 2017 to July 2020. After complete staging workup, the GBC biopsy samples paraffin block was tested for molecular markers estrogen receptor (ER), progesterone receptor (PR), p53, p16, Human epidermal growth factor receptor 2 (HER 2-neu), Survivin, Enhancer of zeste homolog-2 (EZH2), and Cyclooxygenase-2 (COX-2) expression by immunohistochemistry.</p><p><strong>Results: </strong>Fifty newly diagnosed patients of carcinoma gall bladder were included in the present study. Age was ranged from 29 - 69 years (mean 53.42). p53 was the most common positive marker in 74% of patients, survivin in 58%, COX-2 in 44%, and p16 in 42% whereas Her 2 neu and EZH-2 were positive in 16% of patients each. None of the patients of GBC were ER or PR positive. There was a significant difference between the various groups in terms of the distribution of histological grade and Her 2 neu (χ<sup>2</sup> = 9.886, <i>P</i> = 0.014) but not with other markers. Furthermore, there was a significant difference in terms of distribution of p16 and p53 with stage (χ<sup>2</sup> = 7.017, <i>P</i> = 0.037 and χ<sup>2</sup> = 5.861, <i>P</i> = 0.033) respectively.</p><p><strong>Conclusions: </strong>The present study shows the expression of molecular markers Her2 neu, p53, p16, survivin, COX-2, and EZH-2 in GBC. Now the time has come, and it is also the need of the day to establish early biomarkers of this highly lethal malignancy. It can be used in future for the detection of disease in the early phase and targeted therapy.</p>","PeriodicalId":52464,"journal":{"name":"Journal of Carcinogenesis","volume":"20 ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312376/pdf/","citationCount":"15","resultStr":"{\"title\":\"Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma.\",\"authors\":\"Amit Gupta, Sweety Gupta, Rishit Mani, Prashant Durgapal, Bela Goyal, Deepak Rajput, Shalinee Rao, Puneet Dhar, Manoj Gupta, Sanjeev Kishore, Ravi Kant\",\"doi\":\"10.4103/jcar.JCar_4_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Gallbladder cancer exhibits striking variability in the global rates, reaching epidemic levels for some regions and ethnicities. The basis of its variability resides in differences in environmental exposure and intrinsic genetic predisposition to carcinogenesis. There is little information present regarding genetic and molecular alterations in gall bladder cancer (GBC). We, therefore, have evaluated the molecular marker expression in GBC and studied their correlation with clinicopathological staging.</p><p><strong>Materials and methods: </strong>This prospective observational study was conducted on newly diagnosed GBC patients from July 2017 to July 2020. After complete staging workup, the GBC biopsy samples paraffin block was tested for molecular markers estrogen receptor (ER), progesterone receptor (PR), p53, p16, Human epidermal growth factor receptor 2 (HER 2-neu), Survivin, Enhancer of zeste homolog-2 (EZH2), and Cyclooxygenase-2 (COX-2) expression by immunohistochemistry.</p><p><strong>Results: </strong>Fifty newly diagnosed patients of carcinoma gall bladder were included in the present study. Age was ranged from 29 - 69 years (mean 53.42). p53 was the most common positive marker in 74% of patients, survivin in 58%, COX-2 in 44%, and p16 in 42% whereas Her 2 neu and EZH-2 were positive in 16% of patients each. None of the patients of GBC were ER or PR positive. There was a significant difference between the various groups in terms of the distribution of histological grade and Her 2 neu (χ<sup>2</sup> = 9.886, <i>P</i> = 0.014) but not with other markers. Furthermore, there was a significant difference in terms of distribution of p16 and p53 with stage (χ<sup>2</sup> = 7.017, <i>P</i> = 0.037 and χ<sup>2</sup> = 5.861, <i>P</i> = 0.033) respectively.</p><p><strong>Conclusions: </strong>The present study shows the expression of molecular markers Her2 neu, p53, p16, survivin, COX-2, and EZH-2 in GBC. Now the time has come, and it is also the need of the day to establish early biomarkers of this highly lethal malignancy. It can be used in future for the detection of disease in the early phase and targeted therapy.</p>\",\"PeriodicalId\":52464,\"journal\":{\"name\":\"Journal of Carcinogenesis\",\"volume\":\"20 \",\"pages\":\"7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312376/pdf/\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Carcinogenesis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcar.JCar_4_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Environmental Science\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Carcinogenesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcar.JCar_4_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Environmental Science","Score":null,"Total":0}
引用次数: 15
摘要
胆囊癌在全球发病率中表现出惊人的差异，在某些地区和种族达到流行病水平。其可变性的基础在于环境暴露的差异和致癌的内在遗传易感性。目前关于胆囊癌(GBC)的遗传和分子改变的信息很少。因此，我们评估了GBC中分子标志物的表达，并研究了它们与临床病理分期的关系。材料与方法:本前瞻性观察研究于2017年7月至2020年7月对新诊断的GBC患者进行研究。完成分期检查后，采用免疫组化方法检测GBC活检标本石蜡块中雌激素受体(ER)、孕激素受体(PR)、p53、p16、人表皮生长因子受体2 (HER 2-neu)、Survivin、zeste同源物增强子-2 (EZH2)、环氧化酶-2 (COX-2)等分子标志物的表达。结果:本研究纳入50例新诊断的胆囊癌患者。年龄29 ~ 69岁，平均53.42岁。在74%的患者中，p53是最常见的阳性标记物，58%的患者为survivin, 44%的患者为COX-2, 42%的患者为p16，而Her 2 neu和EZH-2分别在16%的患者中呈阳性。GBC患者均无ER或PR阳性。各组间组织学分级和Her 2 neu分布差异有统计学意义(χ2 = 9.886, P = 0.014)，其他指标差异无统计学意义。p16、p53的分期分布差异有统计学意义(χ2 = 7.017, P = 0.037; χ2 = 5.861, P = 0.033)。结论:本研究显示GBC中存在Her2 neu、p53、p16、survivin、COX-2、EZH-2等分子标记的表达。现在时机已经成熟，建立这种高度致命的恶性肿瘤的早期生物标志物也是当今的需要。未来可用于疾病的早期检测和靶向治疗。
Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma.
Introduction: Gallbladder cancer exhibits striking variability in the global rates, reaching epidemic levels for some regions and ethnicities. The basis of its variability resides in differences in environmental exposure and intrinsic genetic predisposition to carcinogenesis. There is little information present regarding genetic and molecular alterations in gall bladder cancer (GBC). We, therefore, have evaluated the molecular marker expression in GBC and studied their correlation with clinicopathological staging.
Materials and methods: This prospective observational study was conducted on newly diagnosed GBC patients from July 2017 to July 2020. After complete staging workup, the GBC biopsy samples paraffin block was tested for molecular markers estrogen receptor (ER), progesterone receptor (PR), p53, p16, Human epidermal growth factor receptor 2 (HER 2-neu), Survivin, Enhancer of zeste homolog-2 (EZH2), and Cyclooxygenase-2 (COX-2) expression by immunohistochemistry.
Results: Fifty newly diagnosed patients of carcinoma gall bladder were included in the present study. Age was ranged from 29 - 69 years (mean 53.42). p53 was the most common positive marker in 74% of patients, survivin in 58%, COX-2 in 44%, and p16 in 42% whereas Her 2 neu and EZH-2 were positive in 16% of patients each. None of the patients of GBC were ER or PR positive. There was a significant difference between the various groups in terms of the distribution of histological grade and Her 2 neu (χ2 = 9.886, P = 0.014) but not with other markers. Furthermore, there was a significant difference in terms of distribution of p16 and p53 with stage (χ2 = 7.017, P = 0.037 and χ2 = 5.861, P = 0.033) respectively.
Conclusions: The present study shows the expression of molecular markers Her2 neu, p53, p16, survivin, COX-2, and EZH-2 in GBC. Now the time has come, and it is also the need of the day to establish early biomarkers of this highly lethal malignancy. It can be used in future for the detection of disease in the early phase and targeted therapy.
期刊介绍：
Journal of Carcinogenesis considers manuscripts in many areas of carcinogenesis and Chemoprevention. Primary areas of interest to the journal include: physical and chemical carcinogenesis and mutagenesis; processes influencing or modulating carcinogenesis, such as DNA repair; genetics, nutrition, and metabolism of carcinogens; the mechanism of action of carcinogens and modulating agents; epidemiological studies; and, the formation, detection, identification, and quantification of environmental carcinogens. Manuscripts that contribute to the understanding of cancer prevention are especially encouraged for submission
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
